Endovastec(SH:688016) Sou Hu Cai Jing·2026-01-28 11:27Core Viewpoint - The financial performance of Xinmai Medical (688016) shows mixed results, with revenue growth but a significant decline in net profit, indicating potential challenges ahead for the company [2]. Financial Performance - For the first three quarters of 2025, Xinmai Medical reported a total revenue of 1.015 billion yuan, an increase of 4.66% year-on-year [2]. - The net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2]. - The net profit after deducting non-recurring items fell by 25.8% to 372 million yuan [2]. - In Q3 2025, the company achieved a quarterly revenue of 300 million yuan, a substantial increase of 64.68% year-on-year [2]. - The quarterly net profit attributable to shareholders was 114 million yuan, down 23.63% year-on-year [2]. - The quarterly net profit after deducting non-recurring items was 102 million yuan, a decrease of 11.84% [2]. - The company's debt ratio stands at 15.85%, with investment income of 11.6033 million yuan and financial expenses of -7.8584 million yuan [2]. - The gross profit margin is reported at 70.4% [2]. Market Activity - As of January 28, 2026, Xinmai Medical's stock closed at 94.0 yuan, down 1.67% with a turnover rate of 1.29% and a trading volume of 15,900 hands, amounting to a transaction value of 150 million yuan [1]. - On January 28, the net outflow of main funds was 10.3432 million yuan, accounting for 6.89% of the total transaction value, while retail funds saw a net outflow of 2.9068 million yuan, making up 1.94% [1]. - Conversely, speculative funds experienced a net inflow of 13.25 million yuan, representing 8.82% of the total transaction value [1]. Analyst Ratings - In the last 90 days, seven institutions have provided ratings for Xinmai Medical, with six giving a "buy" rating and one an "increase" rating [2]. - The average target price set by institutions over the past 90 days is 1.3603 billion yuan [2].